Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising new test spots hidden virus after transplant

NCT ID NCT07181330

Diagnosis Sponsor: Ting YANG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a new blood test that looks for a tiny piece of the CMV virus's genetic material (a microRNA) in 60 patients who had a stem cell transplant. The goal was to see if this test could detect CMV reactivation earlier or more accurately than the standard DNA test. Researchers used stored blood samples and compared the new test results to the standard method.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SE-SPTM-PCR microRNA assay (a blood test)
What this could lead to
If successful, this test could provide a more sensitive way to detect CMV reactivation early after stem cell transplant, potentially improving patient outcomes.
What could go wrong
This is a small, retrospective study using stored samples, so results may not apply to all patients. The test is still experimental and needs larger prospective studies to confirm its usefulness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

May 2021

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) and had archived plasma samples collected within 100 days after transplantation. All participants had corresponding cytomegalovirus (CMV) DNA testing results available. Samples were retrospectively analyzed to assess the diagnostic performance of hcmv-miR-UL22A-5p using the SE-SPTM-PCR platform.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients who received allogeneic hematopoietic stem cell transplantation (HSCT) Availability of archived plasma samples collected within 100 days post-transplant Documented CMV DNA testing results corresponding to the plasma sample Age ≥ 18 years Exclusion Criteria: Lack of corresponding CMV DNA testing results Inadequate volume or quality of archived plasma sample for analysis Concurrent active infections with other viruses (e.g., EBV, HBV, HCV) at time of plasma collection Patients who received investigational antiviral therapy within 2 weeks prior to sample collection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allogeneic hematopoietic stem cell transplantation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allogeneic hematopoietic stem cell transplantation CMV reactivation Cytomegalovirus infections Hematopoietic stem cell transplantation (HSCT)

Contacts and locations

Locations

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, 350001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.